Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.58 |
| ▸ | NCF1 | P14598 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.55 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1936053 | 0.95 | NCF1 (0.54) | HRH3CHRM1HTR2AMCHR1NCF1 | |
| SCHEMBL5500400 | 0.85 | ALDH1A1 (0.68) | HRH3CHRM1HTR2AMCHR1NCF1 | |
| SCHEMBL27678490 | 0.84 | ALDH1A1 (0.71) | HRH3ALDH1A1MLLT1KMT2A | |
| SCHEMBL2236992 | 0.83 | ALDH1A1 (0.65) | HRH3CHRM1HTR2AMCHR1NCF1 | |
| SCHEMBL22145190 | 0.82 | ALDH1A1 (0.76) | CHRM1HTR2AMCHR1ALDH1A1HDAC1 | |
| SCHEMBL1936132 | 0.82 | MCHR1 (0.61) | HRH3CHRM1HTR2AMCHR1ALDH1A1 | |
| SCHEMBL21392801 | 0.82 | NCF1 (0.56) | HRH3CHRM1HTR2AMCHR1NCF1 | |
| SCHEMBL3440319 | 0.81 | NCF1 (0.58) | HRH3CHRM1HTR2AMCHR1NCF1 | |
| SCHEMBL13211709 | 0.79 | HDAC1 (0.62) | CHRM1HTR2AMCHR1ALDH1A1KDM4E | |
| SCHEMBL1444172 | 0.79 | NCF1 (0.56) | HRH3CHRM1HTR2AMCHR1NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | HRH3 11/4885CHRM1 55/4885HTR2A 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.